• CLEVELAND, OHIO
  • 1-866-UH4-CARE
  • |
  • Search UH Online
Patients & Visitors Clinical Trials Listing
Print this pageEmail this pageBookmark Page

In This Section

Contact Information

General Phone Number
888-844-8447
216-844-8447
Mailing Address
11100 Euclid Avenue
Cleveland, OH 44106
Clinical Trials

Trial Name:

CASE 1205
Intro: Dose-Dense and Dose-Intense Alternating Irinotecan/Capecitabine and Oxaliplatin/Capecitabine: Phase I in Solid Tumors and Phase II with Bevacizumab as First-Line Therapy of Advanced Colorectal Cancer
Condition:
Description: This study will determine the maximum tolerated dose of Oxaliplatin, Irinotecan, and Capecitabine when given every 2 weeks, and determine if they will lead to improved response rates as first line therapy of advanced colorectal cancer.
Criteria:
  1. Age > 18 years
  2. Phase I: Patients must have a histologically confirmed solid tumor cancer which is metastatic or locally advanced and unresectable, Phase II: Patients must have advanced colorectal cancer
  3. Life expectancy > 12 weeks
  4. Patients must have normal bone marrow, liver and kidney function
Contact: For Cancer Information, Current Clinical Trials, and Referral to a Physician please call (216) 844-5432 or (800) 641-2422

Participant Confidentiality:

All information regarding participation in Clinical Trials is treated with the utmost confidentiality. University Hospitals Case Medical Center and the Division of Clinical Research recognize and respect the confidentiality of this information. Access to information related to clinical trials and their participants is restricted to authorized clinical trials personnel only.

Back